Shopping Cart 0
Cart Subtotal
AED 0

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Novavax Inc (NVAX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a wide range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax's clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and operates a subsidiary in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc Key Recent Developments

Jun 04,2019: Novavax CFO John Trizzino to discuss future of influenza vaccines on industry panel at 2019 BIO International Convention

May 02,2019: Novavax reports first quarter 2019 financial results

Dec 04,2018: Novavax announces leadership promotions

Nov 12,2018: Novavax expands leadership with several key management promotions

Nov 07,2018: Novavax reports third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Novavax Inc-Key Facts

Novavax Inc-Key Employees

Novavax Inc-Key Employee Biographies

Novavax Inc-Major Products and Services

Novavax Inc-History

Novavax Inc-Company Statement

Novavax Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Novavax Inc-Business Description

Novavax Inc-Corporate Strategy

Novavax Inc-SWOT Analysis

SWOT Analysis-Overview

Novavax Inc-Strengths

Novavax Inc-Weaknesses

Novavax Inc-Opportunities

Novavax Inc-Threats

Novavax Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novavax Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 04, 2019: Novavax CFO John Trizzino to discuss future of influenza vaccines on industry panel at 2019 BIO International Convention

May 02, 2019: Novavax reports first quarter 2019 financial results

Dec 04, 2018: Novavax announces leadership promotions

Nov 12, 2018: Novavax expands leadership with several key management promotions

Nov 07, 2018: Novavax reports third quarter 2018 financial results

Nov 01, 2018: Novavax appoints Rachel King to Board of Directors

Aug 28, 2018: Novavax to participate at two upcoming investor conferences

Aug 08, 2018: Novavax Reports second quarter 2018 financial results

May 09, 2018: Novavax Reports First Quarter 2018 Financial Results

Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Novavax Inc, Performance Chart (2014-2018)

Novavax Inc, Ratio Charts

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Novavax Inc, Key Facts

Novavax Inc, Key Employees

Novavax Inc, Key Employee Biographies

Novavax Inc, Major Products and Services

Novavax Inc, History

Novavax Inc, Other Locations

Novavax Inc, Subsidiaries

Novavax Inc, Joint Venture

Novavax Inc, Key Competitors

Novavax Inc, Ratios based on current share price

Novavax Inc, Annual Ratios

Novavax Inc, Annual Ratios (Cont...1)

Novavax Inc, Interim Ratios

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novavax Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Novavax Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Sanofi Pasteur SA

Novartis AG

Mymetics Corp

Merck & Co Inc

GlaxoSmithKline Plc

Company Profile

Company Profile Title

Novavax Inc (NVAX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a wide range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax's clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and operates a subsidiary in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc Key Recent Developments

Jun 04,2019: Novavax CFO John Trizzino to discuss future of influenza vaccines on industry panel at 2019 BIO International Convention

May 02,2019: Novavax reports first quarter 2019 financial results

Dec 04,2018: Novavax announces leadership promotions

Nov 12,2018: Novavax expands leadership with several key management promotions

Nov 07,2018: Novavax reports third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Novavax Inc-Key Facts

Novavax Inc-Key Employees

Novavax Inc-Key Employee Biographies

Novavax Inc-Major Products and Services

Novavax Inc-History

Novavax Inc-Company Statement

Novavax Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Novavax Inc-Business Description

Novavax Inc-Corporate Strategy

Novavax Inc-SWOT Analysis

SWOT Analysis-Overview

Novavax Inc-Strengths

Novavax Inc-Weaknesses

Novavax Inc-Opportunities

Novavax Inc-Threats

Novavax Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novavax Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 04, 2019: Novavax CFO John Trizzino to discuss future of influenza vaccines on industry panel at 2019 BIO International Convention

May 02, 2019: Novavax reports first quarter 2019 financial results

Dec 04, 2018: Novavax announces leadership promotions

Nov 12, 2018: Novavax expands leadership with several key management promotions

Nov 07, 2018: Novavax reports third quarter 2018 financial results

Nov 01, 2018: Novavax appoints Rachel King to Board of Directors

Aug 28, 2018: Novavax to participate at two upcoming investor conferences

Aug 08, 2018: Novavax Reports second quarter 2018 financial results

May 09, 2018: Novavax Reports First Quarter 2018 Financial Results

Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Novavax Inc, Performance Chart (2014-2018)

Novavax Inc, Ratio Charts

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Novavax Inc, Key Facts

Novavax Inc, Key Employees

Novavax Inc, Key Employee Biographies

Novavax Inc, Major Products and Services

Novavax Inc, History

Novavax Inc, Other Locations

Novavax Inc, Subsidiaries

Novavax Inc, Joint Venture

Novavax Inc, Key Competitors

Novavax Inc, Ratios based on current share price

Novavax Inc, Annual Ratios

Novavax Inc, Annual Ratios (Cont...1)

Novavax Inc, Interim Ratios

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Novavax Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Novavax Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Sanofi Pasteur SA

Novartis AG

Mymetics Corp

Merck & Co Inc

GlaxoSmithKline Plc